ACTR707

ACTR707 is an autologous, genetically modified T cell therapy developed using proprietary Antibody-Coupled T-cell Receptor (ACTR) technology. The therapy involves engineering a patient’s own T lymphocytes to express a chimeric receptor composed of the extracellular domain of CD16, a CD28 co-stimulatory domain, and a CD3ζ signaling domain. This design enables the modified T cells to be activated in the presence of tumor-targeting antibodies such as rituximab or trastuzumab, thereby combining the cytotoxic potential of T cells with the specificity provided by monoclonal antibodies. The primary mechanism is immunologic cytotoxicity mediated by antibody-dependent cellular cytotoxicity (ADCC), targeting cancer cells marked by therapeutic antibodies. ACTR707 has been evaluated primarily for relapsed/refractory B cell non-Hodgkin lymphoma in combination with rituximab and has also been studied in HER2-positive advanced cancers with trastuzumab[2][3][4][6][7].

Other names

autologous ACTR-CD16-CD28-expressing T lymphocytesantibody-coupled T cell receptor 707